SCHEMBL276550

SCHEMBL276550

COc1ccc(Br)c(F)c1C=O

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 7/20 0.59
PRKDC P78527 1/20 0.47
ALDH1A1 P00352 6/20 0.40
TSHR P16473 1/20 0.40
KDM4E B2RXH2 1/20 0.38
PTPRF P10586 1/20 0.37
AOX1 Q06278 1/20 0.37
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TUBB1 Q9H4B7 1/20 0.35
FDPS P14324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30853338 1.00 ERN1 (0.59) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL565717 0.85 ERN1 (0.64) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL1478225 0.84 ERN1 (0.47) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL30826221 0.81 ERN1 (0.62) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL911855 0.81 ERN1 (0.44) ERN1ALDH1A1TSHRPTPRFAOX1
SCHEMBL5552745 0.79 ERN1 (0.61) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL1888264 0.79 ERN1 (0.61) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL19792605 0.79 ERN1 (0.43) ERN1PRKDCALDH1A1TSHRKDM4E
SCHEMBL28057376 0.79 ERN1 (0.43) ERN1ALDH1A1TSHRPTPRFAOX1
SCHEMBL16797103 0.79 ERN1 (0.40) ERN1PRKDCMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4687880-A1 ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT Tactogen Inc. (US) 2026-02-11 EP disclosed
US-20260021069-A1 ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2026-01-22 US disclosed
EP-4680612-A1 CHEMICAL COMPOUNDS AN2 Therapeutics, Inc. (US) 2026-01-21 EP disclosed
US-20250382312-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF BORAH INC (US) 2025-12-18 US disclosed
US-12404286-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof BORAH, INC. (US) 2025-09-02 US disclosed
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
US-20240352045-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) 2024-10-24 US disclosed
WO-2024206712-A1 ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC. (US) 2024-10-03 WO disclosed
WO-2024192309-A1 CHEMICAL COMPOUNDS REACTIVE BIOSCIENCES, INC. (US) 2024-09-19 WO disclosed
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382312-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF JAK3, JAK1, JAK2 ERN1 1139/4885PRKDC 432/4885ALDH1A1 3977/4885
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT ERN1 2608/4885PRKDC 3205/4885ALDH1A1 138/4885
US-20260021069-A1 ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT HCN1, HCN4, CRH ERN1 2728/4885PRKDC 3914/4885ALDH1A1 724/4885
US-20240352045-A1 BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF JAK3, JAK1, JAK2 ERN1 1139/4885PRKDC 432/4885ALDH1A1 3977/4885
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A ERN1 1523/4885PRKDC 1133/4885ALDH1A1 3523/4885
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 ERN1 478/4885PRKDC 883/4885ALDH1A1 3733/4885
US-12404286-B2 Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof JAK3, JAK1, JAK2 ERN1 1139/4885PRKDC 432/4885ALDH1A1 3977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.